Demetrix scales up CBG production capabilities

Biotech company Demetrix has hit a big milestone in its efforts to commercialize the rare cannabinoid cannabigerol, or CBG. The Berkeley, Calif.-based company said that it had commenced 15,000-liter demo-scale production of CBG following several successful pilot-scale fermentations.

Read the full article HERE

Rare Bio-Actives – Beyond CBD

Read More
Commercializing Rare Cannabinoids

The Path to Commercializing Rare Bioactives

Read More
Strain Engineering

Rare Access: Strain Engineering

Read More
Structure of CBGA on blue background

CBGA – The Mother Cannabinoid

Read More
The Skin Microbiome

The Skin Microbiome – Part 2

Read More
Demetrix CEO Jeff Ubersax lab

CEO Jeff Ubersax Discusses Cannabinoid sustainability

Read More